A Carrier-Free Peptide Nanomedicine Orchestrates Dual Redox Therapy via Ferroptosis and Disulfidptosis
ACS Applied Materials & Interfaces · 2026
DOI: 10.1021/acsami.6c08792 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Applied Materials & Interfaces, 2026. Verfasst von Yuting Kong und 6 weiteren Autor:innen. Beteiligte Einrichtung: Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University,…. Hauptthemen laut MEDLINE: Ferroptosis, Disulfidptosis, Peptides, Nanoparticles. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Natural Science Foundation of Tianjin Municipality, Young Scientific and Technological Talents in Tianjin.
Abstract (Originalsprache)
Carrier-free nanomedicines offer a promising strategy to simplify formulation while maximizing therapeutic function. Here, we report a disulfide-containing self-assembling peptide, Fmoc-Cys(StBu)-Phe-Phe-Tyr-Lys-Cys(StBu) (Fmoc-S-S), as a minimalist nanomedicine for dual redox cancer therapy. Fmoc-S-S spontaneously formed uniform spherical nanoparticles with favorable hemocompatibility, glutathione-responsive structural transformation, and enhanced tumor accumulation in vivo. Mechanistically, Fmoc-S-S disrupted intracellular redox homeostasis by depleting glutathione, altering the NADP+/NADPH balance, suppressing SLC7A11 and GPX4, promoting lipid peroxidation, and reducing mitochondrial membrane potential, consistent with ferroptosis induction. Meanwhile, biochemical evidence of intracellular disulfide stress, including decreased cysteine levels, together with partial rescue by dithiothreitol and marked F-actin disruption, supported the involvement of disulfidptosis. In MC38 tumor-bearing mice, Fmoc-S-S nanoparticles significantly inhibited tumor growth without obvious systemic toxicity. Proteomic analysis further revealed coordinated dysregulation of pathways associated with glutathione metabolism, mitochondrial function, oxidative phosphorylation, and cytoskeletal organization. Together, this work presents a self-assembled peptide biomaterial that integrates nanostructure formation, tumor delivery, and dual induction of ferroptosis and disulfidptosis within a single carrier-free system, providing a new strategy for redox-directed cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin300070, China.
- Tianjin Key Laboratory of Biosensing and Molecular Recognition, Research Center for Analytical Science, College of Chemistry, Nankai University, Tianjin300071, China.
ORCID-Profile: Gongyu Li, Zhen Zheng
Förderung
- Natural Science Foundation of Tianjin Municipality
- Young Scientific and Technological Talents in Tianjin
Zitieren
APA
Kong, Y., Peng, L., Liang, T., Yan, J., Huang, X., Li, G., & Zheng, Z. (2026). A Carrier-Free Peptide Nanomedicine Orchestrates Dual Redox Therapy via Ferroptosis and Disulfidptosis. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.6c08792
Vancouver
Kong Y, Peng L, Liang T, Yan J, Huang X, Li G, et al. A Carrier-Free Peptide Nanomedicine Orchestrates Dual Redox Therapy via Ferroptosis and Disulfidptosis. ACS Applied Materials & Interfaces. 2026. doi:10.1021/acsami.6c08792
BibTeX
@article{Kong2026,
author = {Kong, Yuting and Peng, Liyuan and Liang, Tingting and Yan, Jingru and Huang, Xuan and Li, Gongyu and Zheng, Zhen},
title = {A Carrier-Free Peptide Nanomedicine Orchestrates Dual Redox Therapy via Ferroptosis and Disulfidptosis},
journal = {ACS Applied Materials & Interfaces},
year = {2026},
doi = {10.1021/acsami.6c08792}
}
EUVIMED